ISPE Launches ATMP Community of Practice
“The only constant in life is change.” This quote is as true today as it was 2,500 years ago when Heraclitus laid out his philosophy. In the last five years, the word “cure” has been used to describe new therapies targeting many different cancer and hereditary diseases. The potential of these therapies to improve human health is profound. These breakthrough therapies utilize advancements in bioengineering that are a step beyond the traditional biopharmaceutical products. A lot of knowledge and experience has been gained from biopharmaceuticals, which can be applied to these new therapies. To advance the scope of diseases treated and evolve the manufacturability of the therapies, a focused effort is needed.